Skip to content
TrialScanner

NCT03923270

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1Active, not recruitingAZNCollaborator

Registry record

Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Conditions
Small Cell Lung Cancer Extensive Stage; Small-cell Lung Cancer
Primary completion
Jun 1, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03923270 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03923270: Radiotherapy and Durvalumab/D... | TrialScanner